News and Announcements
QBiotics Raises $22.1m. ASX & Cochlear Chairman Joins Board
- Published February 01, 2017 12:54PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
QLD based QBiotics, who are developing drugs targeting cancer and wound healing, raised a total of $22.1m in 2016.
Their Board has also been strengthened with the addition of Rick Holiday-Smith as Chairman (ASX; Cochlear) as well as Dr Bruce Robinson (Mayne Pharma) and Andrew Denver (Cochlear) as non-exec Directors.
ABOUT QBIOTICS
QBiotics Limited is developing a pipeline of promising drugs in the area of cancer and wound healing. Its lead drug, EBC-46, targets solid tumours and is currently in late pre-clinical development in preparation for a Human Clinical Phase I/II trial with the USA’s FDA. EBC-46 is also in late stage development for the veterinary market through the USA’s FDA-CVM.